About
Michael J. LaBarre served as Senior Vice President, Chief Technical Officer of Halozyme Therapeutics. On March 17, 2025, he notified the Company of his decision to retire, effective March 17, 2025, after many years of service and contributions to the Company's ENHANZE drug delivery technology.
Roles
Halozyme Therapeutics, Inc.
Former Senior Vice President, Chief Technical Officer · Current role
Present
Paramount BioSciences
Vice President of Product Development
—
Biogen Idec (IDEC)
Research and development positions
1995-2006
Fixed Compensation
FY 2025
All other compensation
$90,237
Total compensation
$2,053,642
Performance Compensation
Data from FY 2025
Stock awards
Also at Halozyme Therapeutics, Inc.